Abbott has announced the results from a study evaluating its High Sensitive Troponin- I (hsTnI) assay which says that it may help doctors predict which patients presenting with symptoms of a heart attack, such as severe chest pain, are at a higher risk for having a heart attack 30 days later.
A concern for patients who present with severe chest pain is that they are more likely to experience another cardiovascular event within a few weeks or months. Researchers evaluated the performance of a hsTnI assay with the performance of a fourth generation troponin T assay among 4,695 patients presenting with severe chest pain and found that the hsTnI assay identified more patients at higher risk of recurrent heart attack.
